FGFR inhibitors
Oral kinase inhibitors for tumours driven by FGFR changes, such as bladder cancer and cholangiocarcinoma. High phosphate and eye effects.
What they are
Erdafitinib treats urothelial carcinoma with FGFR3 alterations; pemigatinib treats cholangiocarcinoma with FGFR2 fusions and myeloid or lymphoid neoplasms with FGFR1 rearrangement. A genomic test is required before treatment.
Mechanism of action
Fibroblast growth factor receptors (FGFR1–4) are receptor tyrosine kinases. Mutations, amplifications or gene fusions can keep them permanently active and drive tumour growth. These drugs occupy the ATP site and block signalling. Inhibiting FGFR also raises blood phosphate in most patients, an on-target effect.
Target: Fibroblast growth factor receptor tyrosine kinases (FGFR1–4)
Drugs in this class
- ErdafitinibAn oral pan-FGFR inhibitor for urothelial cancer with FGFR3 changes. Raises blood phosphate and harms the eyes, skin…Fibroblast growth factor receptor kinases (FGFR1–4)
- PemigatinibAn oral FGFR1–3 inhibitor for cholangiocarcinoma with FGFR2 fusions and for rare FGFR1-rearranged blood cancers. High…Fibroblast growth factor receptor kinases (FGFR1–3)
Others in the class
- Infigratinib
Test yourself
Think of the answer, then tap the question to see it.
Is the high blood phosphate on FGFR inhibitors an off-target effect?
No: it is an on-target consequence of FGFR inhibition, so phosphate is measured and the diet adjusted.
Which FGFR alteration is targeted in cholangiocarcinoma?
FGFR2 fusions or rearrangements.
Which examination is repeated on FGFR inhibitors?
Eye examination of the retina.
Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.
Sources: ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026); Erdafitinib: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); Pemigatinib: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.